KYNMOBI

This brand name is authorized in United States. It is also authorized in Canada.

Active ingredients

The drug KYNMOBI contains one active pharmaceutical ingredient (API):

1	Apomorphine UNII F39049Y068 - APOMORPHINE HYDROCHLORIDE
	Apomorphine is a direct stimulant of dopamine receptors and while possessing both D1 and D2 receptor agonist properties does not share transport or metabolic pathways with levodopa. Its actions on parkinsonian motor disability are likely to be mediated at post-synaptic receptor sites.
	Read more about Apomorphine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
KYNMOBI Sublingual film	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N04BC07	Apomorphine	N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BC Dopamine agonists
Discover more medicines within N04BC07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02500264, 02500272, 02500280, 02500299, 02500302
US	FDA, National Drug Code	63402-010, 63402-015, 63402-020, 63402-025, 63402-030, 63402-110, 63402-115, 63402-120, 63402-125, 63402-130